A Letter from our CEO

Welcome to Titan Pharmaceuticals.

At Titan, we are focused on developing innovative therapies that will make a meaningful impact in the lives of people suffering from diseases of the central nervous system. We are currently focused on three late-stage development programs for treatments of schizophrenia, opiate addiction and Parkinson’s Disease.

We are committed to applying the highest standards in the development of new medicines as we bring these products closer to patients. Toward that goal, we anticipate meeting important development milestones for our programs in the second half of 2008.

2008 will be an exciting year for Titan, and I am very enthusiastic about our potential moving forward. I invite you to learn more about Titan by exploring our website, and I look forward to sharing new information with you as our programs progress.

Best,
Marc Rubin, M.D.,
President and CEO

Latest News

July 02, 2008
Titan Pharmaceuticals Announces Spheramine(R) Initial Phase IIb Results

June 24, 2008
Titan Pharmaceuticals Announces Spheramine(R) Presentations at 12th International Congress of Parkinson's Disease and Movement Disorders

May 12, 2008
Titan Pharmaceuticals Announces First Quarter 2008 Financial Results

May 05, 2008
Titan Pharmaceuticals to Host Conference Call on First Quarter 2008 Financial Results

Patient Resources

At Titan, we are committed to developing breakthrough medicines to meet the needs of patients struggling with life-altering diseases. We understand that access to information regarding diseases and clinical trials is essential to patients and their caregivers, so please view our Clinical Trials page for information regarding our ongoing clinical trials. For additional information on our diseases of focus, please view the links below: